Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014551320> ?p ?o ?g. }
- W3014551320 endingPage "967" @default.
- W3014551320 startingPage "953" @default.
- W3014551320 abstract "There is an unmet medical need for an effective anti-fibrotic treatment for NASH with advanced fibrosis.The authors review the current and novel agents for the treatment of NASH with fibrosis. They also consider the potential future strategies of combination therapies.Farnesoid X receptor (FXR) agonist (obeticholic acid [OCA]) significantly ameliorated hepatic fibrosis in NASH stage 2/3 fibrosis in an interim analysis of phase 3 trial. Because OCA has several drawbacks such as itching and elevated low-density lipoprotein-cholesterol (LDL-C), non-bile acid FXR agonists are now under development. Selonsertib (apoptosis signaling kinase 1 inhibitor), emricasan (an irreversible pan-caspase inhibitor), and simtsuzumab (a monoclonal antibody against lysyl oxidase-like 2) were discontinued because of no efficacy over placebo. Peroxisome proliferator-activator receptor α/δ agonists, C-C motif chemokine receptor-2/5 antagonists, and thyroid β receptor agonist are ongoing in phase 3 trials. A variety of agents including fibroblast growth factor (FGF)-21 and FGF-19 agonists, as well as acetyl-CoA carboxylase inhibitors, are also expected. Among antidiabetic agents, semaglutide, a novel GLP-1 RA, is ongoing for NASH stage 1-3 fibrosis in a phase 2 trial. Furthermore, the combination of GLP-RA/glucagon receptor agonist and GLP-RA/gastrointestinal peptide agonist are promising future options." @default.
- W3014551320 created "2020-04-10" @default.
- W3014551320 creator A5002514925 @default.
- W3014551320 creator A5002837555 @default.
- W3014551320 creator A5017078328 @default.
- W3014551320 creator A5029497173 @default.
- W3014551320 creator A5041533806 @default.
- W3014551320 creator A5067227542 @default.
- W3014551320 date "2020-04-01" @default.
- W3014551320 modified "2023-10-18" @default.
- W3014551320 title "Current and new pharmacotherapy options for non-alcoholic steatohepatitis" @default.
- W3014551320 cites W1539520316 @default.
- W3014551320 cites W1555526329 @default.
- W3014551320 cites W1588940501 @default.
- W3014551320 cites W1899648783 @default.
- W3014551320 cites W1901029932 @default.
- W3014551320 cites W1964063591 @default.
- W3014551320 cites W1972184436 @default.
- W3014551320 cites W1987539891 @default.
- W3014551320 cites W1987555708 @default.
- W3014551320 cites W1998156781 @default.
- W3014551320 cites W1999405492 @default.
- W3014551320 cites W2003623208 @default.
- W3014551320 cites W2012868945 @default.
- W3014551320 cites W2014830013 @default.
- W3014551320 cites W2039105369 @default.
- W3014551320 cites W2062842771 @default.
- W3014551320 cites W2068581556 @default.
- W3014551320 cites W2081095734 @default.
- W3014551320 cites W2084722601 @default.
- W3014551320 cites W2086113980 @default.
- W3014551320 cites W2086825927 @default.
- W3014551320 cites W2092700213 @default.
- W3014551320 cites W2108347074 @default.
- W3014551320 cites W2112044211 @default.
- W3014551320 cites W2113983413 @default.
- W3014551320 cites W2132596222 @default.
- W3014551320 cites W2132715587 @default.
- W3014551320 cites W2166264058 @default.
- W3014551320 cites W2204688218 @default.
- W3014551320 cites W2214871873 @default.
- W3014551320 cites W2215535790 @default.
- W3014551320 cites W2253420963 @default.
- W3014551320 cites W2280192011 @default.
- W3014551320 cites W2338295645 @default.
- W3014551320 cites W2338564836 @default.
- W3014551320 cites W2508765586 @default.
- W3014551320 cites W2509864751 @default.
- W3014551320 cites W2518389324 @default.
- W3014551320 cites W2519510391 @default.
- W3014551320 cites W2523163592 @default.
- W3014551320 cites W2535633630 @default.
- W3014551320 cites W2554727807 @default.
- W3014551320 cites W2560450505 @default.
- W3014551320 cites W2579276161 @default.
- W3014551320 cites W2580009538 @default.
- W3014551320 cites W2588037944 @default.
- W3014551320 cites W2606051452 @default.
- W3014551320 cites W2613374020 @default.
- W3014551320 cites W2613626672 @default.
- W3014551320 cites W2626534878 @default.
- W3014551320 cites W2732922894 @default.
- W3014551320 cites W2734724639 @default.
- W3014551320 cites W2737083386 @default.
- W3014551320 cites W2740884150 @default.
- W3014551320 cites W2741416895 @default.
- W3014551320 cites W2742155329 @default.
- W3014551320 cites W2742852552 @default.
- W3014551320 cites W2743667261 @default.
- W3014551320 cites W2746863374 @default.
- W3014551320 cites W2753877565 @default.
- W3014551320 cites W2754550313 @default.
- W3014551320 cites W2755899227 @default.
- W3014551320 cites W2761787658 @default.
- W3014551320 cites W2768977224 @default.
- W3014551320 cites W2769380893 @default.
- W3014551320 cites W2775135060 @default.
- W3014551320 cites W2787255324 @default.
- W3014551320 cites W2787846545 @default.
- W3014551320 cites W2790667037 @default.
- W3014551320 cites W2792505913 @default.
- W3014551320 cites W2793275191 @default.
- W3014551320 cites W2799863868 @default.
- W3014551320 cites W2800547925 @default.
- W3014551320 cites W2800833440 @default.
- W3014551320 cites W2803710234 @default.
- W3014551320 cites W2804125934 @default.
- W3014551320 cites W2805588616 @default.
- W3014551320 cites W2806668158 @default.
- W3014551320 cites W2808958607 @default.
- W3014551320 cites W2809716709 @default.
- W3014551320 cites W2821544409 @default.
- W3014551320 cites W2883362011 @default.
- W3014551320 cites W2884837248 @default.
- W3014551320 cites W2886911834 @default.
- W3014551320 cites W2892632954 @default.
- W3014551320 cites W2895666357 @default.
- W3014551320 cites W2902465653 @default.